The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
BACKGROUND
This study sought to test the effectiveness of EVOSKIN®Palm and sole moisturizing cream (PSMC) in preventing and treating hand-foot syndrome (HFS) during capecitabine chemotherapy.


METHODS
Stage II/III colorectal cancer patients receiving capecitabine adjuvant chemotherapy were randomly allocated to receive either EVOSKINPSMC or physiological saline treatments for their hands and feet. Treatment was initiated along with adjuvant chemotherapy and continued till the end of chemotherapy. Participants' skin responses were evaluated every 3 weeks.


RESULTS
During the study, 51 participants in the EVOSKIN PSMC group and 54 participants in the physiological saline group completed at least three cycles of capecitabine chemotherapy. The total incidence of HFS in the EVOSKIN PSMC group was lower than that in the physiological saline group (56.8% vs. 75.9%, P=0.006), as was the incidence of Grade 3/4 HFS (6.0% vs. 18.5%, P=0.011). The incidence of HFS became significant after 6weeks of chemotherapy. Further, the incidence of severe HFS was significant from as early as 3weeks after the commencement of chemotherapy despite the use of EVOSKIN PSMC to manage the condition. Notably, the incidence of Grade 1/2 HFS was not statistically significant between the two groups (26/51 vs. 32/54, 52.0% vs. 59.2%, P=0.194).


CONCLUSIONS
The incidence of severe HFS among individuals using oral capecitabine can be reduced by the prophylactic treatment of EVOSKIN PSMC, this treatment is reasonable and acceptable for patients with capecitabine chemotherapy.
['Lu|Weiqun|W|', 'Huang|Zhiliang|Z|', 'Chen|Shicai|S|', 'Lv|Huizeng|H|', 'Chen|Xinqi|X|', 'Lei|Jian|J|', 'Ke|Chuanfeng|C|', 'Hong|Chuyuan|C|', 'Wei|Yisheng|Y|', 'Su|Rong|R|', 'Chen|Rong|R|', 'Sun|Zheng|Z|', 'Yang|Ping|P|', 'Tan|Xiaojun|X|', 'Liu|Haiying|H|']
D000964:Antimetabolites, Antineoplastic D000069287:Capecitabine D017024:Chemotherapy, Adjuvant D015179:Colorectal Neoplasms D060831:Hand-Foot Syndrome D006801:Humans
prevention Hand-foot syndrome (HFS) capecitabine colorectal cancer